Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ontario Health Technology Advisory Committee (OHTAC). Prolaris cell cycle progression test for localized prostate cancer: OHTAC Recommendation. Toronto: Health Quality Ontario (HQO). 2017 Authors' conclusions After considering the available evidence on clinical utility, budget impact, and lived experience,
as well as patient preferences and values, the committee reached consensus that there is
uncertainty about the potential clinical benefits of this test. The clinical evidence is limited, there
is uncertainty about its generalizability, and there remains an important gap in information on
how adding this test to clinical practice in Ontario would affect patient-important outcomes, such
as quality of life or mortality. In addition, the test is expensive, both on an individual basis and in
terms of the total budget impact. Indexing Status Subject indexing assigned by CRD MeSH Cell Division; Humans; Male; Prostatic Neoplasms Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca AccessionNumber 32017000348 Date abstract record published 04/09/2017 |